Tennent Institute of Ophthalmology, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom.
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.
PLoS Negl Trop Dis. 2024 Nov 18;18(11):e0012535. doi: 10.1371/journal.pntd.0012535. eCollection 2024 Nov.
Trachoma is the leading infectious cause of blindness. Patients with trachomatous corneal opacity (TCO) are traditionally considered high-risk cases for graft failure. However, anecdotal evidence suggests that corneal transplantation may restore vision in such individuals. We wanted to review the available evidence for keratoplasty outcomes in TCO.
A literature search of PubMed, MEDLINE, and Web of Science was performed using the search terms "trachoma* AND (keratoplasty OR cornea* transplant*)". The search was restricted to studies published between 1 January 1992 and 12 October 2022. All types of prospective and retrospective study designs reporting outcomes of keratoplasty in trachoma were included. The primary outcome assessed was rate of graft survival in patients with TCO who received keratoplasty. Secondary outcomes were postoperative best corrected visual acuity (BCVA) and graft rejection rates.
Seven studies met our inclusion criteria. None were prospective trials; 215/302 grafts (71%) were clear at final follow-up. There was significant variability between studies in the reporting of patient characteristics, follow-up, complications, and outcomes. In data on penetrating keratoplasty (PKP), graft survival at final follow-up was observed in 161/195 eyes (83%). Studies assessing lamellar keratoplasty (LKP) reported graft survival in 18/20 eyes (90%). Rejection episodes were reported in 31/167 (19%) eyes managed with PKP and 0 of 20 eyes managed with LKP. Of 163 eyes, preoperative BCVA was ≤counting fingers in 76% and ≤6/60 in 91%. A postoperative BCVA of >6/60 was achieved in 63% of eyes.
There is a paucity of evidence supporting keratoplasty in TCO. However, it may hold visual rehabilitation promise for people whose needs have to date been largely ignored. More structured reporting of outcomes from centres which perform keratoplasty in TCO and a well-designed prospective study would be valuable additions to the literature.
沙眼是导致失明的主要传染病。患有沙眼性角膜混浊(TCO)的患者传统上被认为是移植物失败的高风险病例。然而,传闻证据表明,角膜移植可能会恢复此类患者的视力。我们希望回顾 TCO 角膜移植结果的现有证据。
使用搜索词“trachoma* AND (keratoplasty OR cornea* transplant*)”在 PubMed、MEDLINE 和 Web of Science 上进行文献检索。搜索限制在 1992 年 1 月 1 日至 2022 年 10 月 12 日期间发表的研究。所有类型的前瞻性和回顾性研究设计都报告了在沙眼患者中进行角膜移植的结果。评估的主要结果是接受角膜移植的 TCO 患者的移植物存活率。次要结果是术后最佳矫正视力(BCVA)和移植物排斥率。
有 7 项研究符合我们的纳入标准。没有前瞻性试验;最终随访时 302 个移植物中有 215 个(71%)清晰。研究之间在报告患者特征、随访、并发症和结果方面存在很大差异。在穿透性角膜移植术(PKP)的数据中,最终随访时观察到 161/195 只眼(83%)的移植物存活。评估板层角膜移植术(LKP)的研究报告了 20 只眼中有 18 只(90%)的移植物存活。在接受 PKP 治疗的 167 只眼中有 31 只(19%)发生排斥反应,而在接受 LKP 治疗的 20 只眼中无排斥反应。在 163 只眼中,术前 BCVA 为≤指数视力的占 76%,≤6/60 的占 91%。术后 BCVA >6/60 的比例为 63%。
支持 TCO 角膜移植的证据很少。然而,对于那些迄今为止需求基本被忽视的人来说,它可能具有视力康复的希望。对在 TCO 中进行角膜移植的中心进行更有组织的结果报告以及精心设计的前瞻性研究,将是对文献的宝贵补充。